Fda Approved Cellular and Gene Therapy Products Hemophilia List 2024: How It Works, Results and What to Expect

As of 2024, the FDA-approved hemophilia gene therapies were Hemgenix for eligible adults with hemophilia B and Roctavian for eligible adults with severe hemophilia A. These are one-time intravenous gene therapies designed to help the liver make more clotting factor, but they are not cellular therapies and do not yet represent a guaranteed permanent cure.

Overview: the FDA-approved hemophilia therapies in 2024

The FDA approved cellular and gene therapy products hemophilia list 2024 included two gene therapies: Hemgenix (etranacogene dezaparvovec-drlb) for certain adults with hemophilia B, approved in 2022, and Roctavian (valoctocogene roxaparvovec-rvox) for certain adults with severe hemophilia A, approved in 2023. There were no FDA-approved stem-cell therapies or other cellular therapies for hemophilia in 2024.

Hemophilia is an inherited bleeding disorder caused by low or absent clotting factor VIII (hemophilia A) or factor IX (hemophilia B). Standard treatment includes replacement clotting factor and, for some people with hemophilia A, non-factor preventive medicines. Gene therapy is a newer option that may reduce bleeding and lessen the need for regular preventive treatment in appropriately selected adults.

These therapies are not interchangeable. The choice depends on the type and severity of hemophilia, previous and current treatments, antibody testing, liver health, and individual goals. A comprehensive bleeding-disorders team can help a person understand whether gene therapy is appropriate alongside established hemophilia care.

What are the currently FDA-approved gene therapies?

Hemgenix is approved for adults with hemophilia B who use factor IX preventive therapy, have current or historical life-threatening bleeding, or have repeated serious spontaneous bleeding episodes. It provides a functional version of the factor IX gene. It is given as a single intravenous infusion.

Roctavian is approved for adults with severe hemophilia A who do not have antibodies against the AAV5 viral vector used by the therapy. It provides a functional factor VIII gene designed to enable liver cells to make factor VIII. It is also administered as a one-time intravenous infusion.

Both products use an adeno-associated virus (AAV) vector. The vector is modified so that it does not cause the illness associated with naturally occurring viruses; it serves as a delivery vehicle for genetic instructions. The treatment does not change the genes passed to children and is not intended to alter reproductive cells.

• Hemgenix: gene therapy for eligible adults with hemophilia B.
• Roctavian: gene therapy for eligible adults with severe hemophilia A and no detectable AAV5 antibodies.
• No FDA-approved cellular or stem-cell therapy: stem-cell treatment is not an established cure for hemophilia.

How hemophilia gene therapy works

In hemophilia, the body cannot produce enough functional clotting factor, which is needed to form stable blood clots. Gene therapy introduces a working copy of the relevant gene into liver cells. The liver is the natural site where clotting factors are normally made.

After infusion, the AAV vector enters liver cells and delivers the genetic instructions. Those cells may then produce factor VIII or factor IX and release it into the bloodstream. Higher factor activity can improve clotting and may reduce spontaneous bleeding, joint bleeding and dependence on routine factor infusions.

The delivered genetic material generally remains outside the cell’s chromosomes rather than being designed to integrate into them. This is one reason that the long-term duration of benefit can vary. Factor levels may decline over time, and some people may need to restart preventive treatment after gene therapy.

Gene therapy does not remove the need for lifelong hemophilia expertise. Regular laboratory tests and clinical follow-up help clinicians measure factor levels, assess liver function, review bleeding events and adjust a person’s care plan safely.

Who may be a candidate and what happens during treatment?

Gene therapy is intended for carefully selected adults, not for everyone with hemophilia. The assessment usually includes confirmation of hemophilia type and severity, a review of bleeding frequency and current prophylaxis, factor inhibitor history, liver tests, viral hepatitis and HIV status, and testing for antibodies to the AAV vector where relevant.

People with significant active liver disease, uncontrolled infection, or certain other medical concerns may not be suitable candidates. The treating team also considers whether a person can attend frequent follow-up visits and have repeated blood testing after infusion. Pregnancy planning and contraception should be discussed because product-specific precautions may apply.

The procedure begins with pre-treatment evaluation and a personalized bleeding-management plan. On the infusion day, the therapy is delivered into a vein over several hours in a specialist setting. The person is observed for infusion-related reactions and is usually able to go home once clinically stable.

Afterward, follow-up is particularly important during the first months. Blood tests monitor liver enzymes and clotting-factor activity. Corticosteroids or other immune-suppressing medicines may be used if liver enzyme elevations suggest an immune response affecting the treated liver cells. Existing factor prophylaxis is stopped or adjusted only under the hematology team’s direction.

Benefits, risks and recovery timeline

The potential benefit of gene therapy is sustained production of clotting factor after one infusion. In clinical studies, many treated participants had fewer bleeding episodes and reduced use of routine factor replacement. Individual results differ, and no treatment can promise a particular factor level, bleeding outcome or duration of benefit.

Most people do not have a prolonged physical recovery period from the infusion itself. They can often return to usual non-strenuous activities within days, depending on how they feel and their clinician’s advice. The longer recovery process is medical monitoring, which can continue regularly for months and, in some cases, for years.

Elevated liver enzymes are among the most important potential side effects. Other possible effects include headache, fatigue, nausea, fever, infusion reactions, and changes in liver-related blood tests. There are also uncertainties about very long-term effectiveness and safety because these treatments are relatively new.

People should not stop clotting-factor prevention, change other medicines, or assume they are protected from bleeding without medical advice. A hematologist may recommend continued access to factor products for breakthrough bleeding, surgery, injuries or periods when factor levels are uncertain.

Can hemophilia be cured with gene therapy?

Gene therapy is not currently considered a guaranteed permanent cure for hemophilia. It may substantially improve clotting-factor levels and reduce bleeding in some eligible adults, sometimes allowing them to reduce or stop routine factor prophylaxis for a period of time. However, responses vary and factor levels can decrease over time.

Hemophilia remains a lifelong condition that requires specialist follow-up. A person who has received gene therapy may still need support for injuries, dental procedures, surgery, pregnancy-related planning, or breakthrough bleeds. They may also need to resume preventive treatment if factor activity falls.

Research continues to improve gene delivery, durability, access for people with pre-existing AAV antibodies, and approaches for children. Until longer-term evidence is available across broader groups of patients, it is most accurate to describe gene therapy as a potentially transformative treatment rather than a definitive cure.

Is there a cure for hemophilia coming soon?

There is no confirmed timeline for a universal, permanent cure for hemophilia. Existing gene therapies represent important progress, but they are currently limited to certain adults and do not work equally for every person. Long-term durability, immune responses and eligibility restrictions remain active areas of study.

Researchers are also studying improved viral vectors, gene editing, non-viral delivery systems and approaches that could be appropriate for more people. These methods are investigational unless they have been approved by a regulator for a specific use. Claims of an unproven “cure” through stem cells or gene treatment should be discussed with a qualified hemophilia specialist.

For now, many people can achieve excellent bleeding prevention with individualized standard care, including factor replacement and other preventive medicines. Treatment decisions are safest when made through a comprehensive hemophilia program that can address medication, laboratory monitoring, musculoskeletal care and emergency planning.

What can stem cells currently fix or cure in 2026?

Stem-cell transplantation is an established treatment for some blood cancers, bone marrow failure disorders and selected inherited immune or blood disorders. It works by replacing unhealthy blood-forming cells with healthy donor or patient-derived cells. It is not a routine or FDA-approved treatment for hemophilia.

For hemophilia, stem-cell approaches remain an area of scientific research rather than standard clinical care. A stem-cell transplant carries significant risks, including serious infection, organ complications and graft-versus-host disease when donor cells are used. Those risks would generally outweigh potential benefits for most people with hemophilia, particularly when effective treatments are available.

People considering any stem-cell intervention should ask whether it is approved for their diagnosis, supported by reliable clinical evidence, and delivered through appropriately regulated care. A hematologist can help interpret research claims and identify evidence-based treatment options.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals provide assessment and treatment planning for international patients with bleeding disorders, including discussions of established and emerging care options.

When to seek medical care

A person with hemophilia should seek urgent medical care for a serious injury, suspected head injury, severe or persistent headache, weakness, repeated vomiting, neck pain, chest pain, breathing difficulty, severe abdominal or back pain, or bleeding that does not respond to their prescribed plan. Urgent assessment is also important for a painful swollen joint or muscle, especially if symptoms are worsening.

Anyone receiving or considering gene therapy should contact their treatment team promptly for fever, rash, breathing symptoms during or after infusion, unusual fatigue, yellowing of the skin or eyes, dark urine, new abdominal discomfort, or any unexpected bleeding. These symptoms do not always indicate a serious complication, but timely review is important.

Routine care with a hematologist remains essential even when bleeding is well controlled. Regular review supports vaccinations, dental and surgical planning, physical activity guidance, joint health, family planning and an up-to-date emergency treatment plan.

Frequently asked questions

What was on the FDA approved cellular and gene therapy products hemophilia list in 2024?

The 2024 FDA-approved gene therapy list for hemophilia included Hemgenix for eligible adults with hemophilia B and Roctavian for eligible adults with severe hemophilia A. No cellular or stem-cell therapy was FDA-approved for hemophilia. Eligibility and safety monitoring requirements differ between the two products.

Is Hemgenix a cure for hemophilia B?

Hemgenix can increase factor IX activity and reduce bleeding and factor-use needs in some eligible adults with hemophilia B. It is not described as a guaranteed permanent cure because treatment response and durability can differ from person to person. Ongoing follow-up with a hemophilia specialist is still required.

Is Roctavian suitable for everyone with hemophilia A?

No. Roctavian is approved for certain adults with severe hemophilia A who do not have detectable antibodies to the AAV5 vector. Liver health, prior treatment history, ability to attend follow-up and other medical factors also influence suitability.

How long does it take to recover after hemophilia gene therapy?

The infusion itself is usually completed in one treatment visit, and many people resume ordinary activities within days if they feel well. However, laboratory monitoring is frequent in the early months and may continue long term. This monitoring is a key part of treatment rather than a sign that physical recovery is prolonged.

Can children receive FDA-approved gene therapy for hemophilia?

The FDA approvals for Hemgenix and Roctavian are for adults, not children. Gene therapy research in younger people is continuing, but treatment decisions for children currently rely on established hemophilia therapies and specialist guidance. A pediatric hematology team can discuss age-appropriate options.

Do people still need factor treatment after gene therapy?

Some people may reduce or stop routine prophylactic factor treatment after gene therapy, but only under their hematology team's direction. Factor products may still be needed for breakthrough bleeding, injuries, operations or if factor levels decline. Every person should maintain an individualized emergency bleeding plan.

References

• U.S. Food and Drug Administration
• Centers for Disease Control and Prevention
• National Hemophilia Foundation
• World Federation of Hemophilia
• National Institutes of Health

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.